Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C15H14N4O
CAS Number:
Molecular Weight:
266.30
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
SMILES string
CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O
InChI key
NQDJXKOVJZTUJA-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
nevirapine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Related Categories
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Nevirapine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
NNRTI (non-nucleoside reverse transcriptase inhibitor) of HIV-1
Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The Ki for inhibition of wild-type RT by Nevirapine is 200 nM.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
[Prevention of mother-to-child transmission with single dose nevirapine and human immunodeficiency virus drug resistance].
Jian-feng Han et al.
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 29(7), 730-733 (2008-11-27)
Juan Carlos Lopez-Delgado et al.
Annals of transplantation, 17(1), 122-127 (2012-04-03)
Acute liver failure (ALF) due to antiretroviral treatment is a rare but a fatal complication in HIV-infected patients. Non-nucleoside retroviral transcriptase inhibitors are known to cause hepatotoxicity and exceptionally acute hepatic failure. We report a case of nevirapine-induced acute liver
Zara Shubber et al.
AIDS (London, England), 27(9), 1403-1412 (2013-01-25)
Since 2002, the WHO has recommended either nevirapine (NVP) or efavirenz (EFV) as part of first-line antiretroviral therapy. These two drugs are known to have differing toxicity profiles, but the risk of these toxicities overall is not well established. We
Emily L Heil et al.
Expert opinion on pharmacotherapy, 12(17), 2713-2718 (2011-11-01)
Nevirapine (NVP) was the first non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV infection and quickly became one of the most extensively used antiretrovirals (ARVs) worldwide. A new extended-formulation of the drug has now been FDA approved
J Ena et al.
HIV medicine, 9(9), 747-756 (2008-07-25)
We performed a meta-analysis to assess the efficacy and safety of switching from protease inhibitor (PI)- to nevirapine (NVP)-based regimens in HIV-infected patients in whom virological suppression had been achieved. Six trials (550 patients) were analysed. The demographics showed that
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service